Home › Companies › RNAC

Cartesian Therapeutics

RNAC Rare disease Lead: Phase 3 3 Biotech Distilled articles ↓

Immunology Neurology Oncology Cell

Most recent annual filing: 2026-03-09

Pipeline (4 active programs)

Descartes-08

Cell Target: BCMA

Myasthenia Gravis Phase 3 intravenous
Antisynthetase Syndrome Phase 2 intravenous

Descartes-08

DC-08

Cell Target: BCMA

Dermatomyositis Phase 1 intravenous

Descartes-15

Cell Target: BCMA

Multiple Myeloma Phase 1 intravenous

Discontinued (1)

Descartes-08 — Systemic Lupus Erythematosus · Company decided to no longer pursue development in SLE to prioritize MG and myositis

Biotech Distilled coverage (3)

2026-06-09 UPDATE: Cartesian Therapeutics (RNAC) - The In Vivo Option Just Got a Clinical Timeline
2026-05-27 UPDATE: Cartesian Therapeutics (RNAC) - The Dilution Gap Just Closed 🔒 Paid
2026-05-25 Cartesian Therapeutics (RNAC) — Scientific Deep Dive for Descartes-08 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.